Brief: G1 Therapeutics Says Trilaciclib Increases Pool Of Memory T Cells In Tumor Microenvironment Responsible For Long Term Immune Surveillance, Efficacy

G1 Therapeutics

04/06/2023 12:16

June 4 (Reuters) - G1 Therapeutics Inc  GTHX.O :
    * TRILACICLIB INCREASES POOL OF MEMORY T CELLS IN TUMOR
MICROENVIRONMENT RESPONSIBLE FOR LONG TERM IMMUNE SURVEILLANCE
AND EFFICACY
    * PHASE 2 MECHANISM OF ACTION TRIAL RESULTS DEMONSTRATE
IMMUNOMODULATORY EFFECTS OF TRILACICLIB IN TUMOR
MICROENVIRONMENT
    * TRILACICLIB CONTINUES TO SHOW A STRONG TOLERABILITY
PROFILE
    * THERE WERE NO ADVERSE EVENTS LEADING TO DISCONTINUATION OF
TRILACICLIB

Source text for Eikon:  ID:nGNX97GhdJ 
Further company coverage:  GTHX.O 

 ((Reuters.Briefs@thomsonreuters.com;))